Skip to main content
Presentation
≥156-Week Apremilast Safety in Psoriasis and Psoriatic Arthritis Patients: Pooled Analysis of the ESTEEM and PALACE Phase 3 Trials. 50th Congress of the Australasian College of Dermatologists (ACD), Sydney, Australia, May 2017.
50th Congress of the Australasian College of Dermatologists (ACD) (2017)
  • J Crowley
  • J Wollenhaupt
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
May, 2017
Citation Information
J Crowley, J Wollenhaupt, Philip Mease and et.al.. "≥156-Week Apremilast Safety in Psoriasis and Psoriatic Arthritis Patients: Pooled Analysis of the ESTEEM and PALACE Phase 3 Trials. 50th Congress of the Australasian College of Dermatologists (ACD), Sydney, Australia, May 2017." 50th Congress of the Australasian College of Dermatologists (ACD) (2017)
Available at: http://works.bepress.com/philip-mease/271/